CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 124 enrolled
Drug / intervention
Telotristat etipratedrug
Likely dose
Telotristat etiprate 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02026063
NCT02026063Phase 3Completed
CompareCT.gov

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Lexicon Pharmaceuticals·interventional·Posted Jan 1, 2014·Updated Sep 17, 2019

In Brief

A Phase 3 clinical trial evaluating Telotristat etiprate for Carcinoid Syndrome. Completed, enrolled 124 participants across 43 sites in 12 countries.

Detailed Summary

The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoid Syndrome
CountriesAustralia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 1, 2014
Enrollment StartJan 14, 2014
Primary CompletionSep 12, 2018
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 12.5 years ago

Interventions

Telotristat etipratedrug

Telotristat etiprate tablet (250 mg)